Categories
Change Password!
Reset Password!
A systematic literature review and network meta-analysis of randomized controlled trials (RCTs) were carried out to investigate the efficacy of galcanezumab (a humanized monoclonal antibody) vs. other drugs to treat episodic cluster headache.
In adults, galcanezumab was found to be more
effective in comparison with verapamil and other therapies as a prophylaxis
therapy to decrease episodic cluster headache attacks.
A systematic literature review and
network meta-analysis of randomized controlled trials (RCTs) were carried out
to investigate the efficacy of galcanezumab (a humanized monoclonal antibody)
vs. other drugs to treat episodic cluster headache.
Databases such as Embase, MEDLINE, and Cochrane Library including RCTs and observational studies were explored. The alteration from the baseline in minimizing attacks of episodic cluster headache while the proportion of responders was utilized to pairwise comparisons of the observational studies was the primary endpoint.
The network meta-analysis was carried out
utilizing a random-effects model and fixed-effect model with deviance
information criterion stated for both the models. For the model having the
lower deviance information criterion, the surface under the cumulative ranking
(SUCRA) was demonstrated.
In the systematic literature review, 3 RCTs and 6 observational studies were incorporated. The Bayesian network meta-analysis was performed on the two RCTs incorporated in the systematic literature review, particularly verapamil and galcanezumab studies.
SUCRA demonstrated that galcanezumab had the highest
probability of being the most effective therapy (probability = 66.33%) in
comparison with placebo (probability = 2.09%) and verapamil (probability =
31.58%). Galcanezumab was found to have the greatest overall probability to be
the 2nd most effective therapy (probability = 88.79%).
Galcanezumab appears to be a valuable
preventive therapy for episodic cluster headache people. Additional
head-to-head RCTs of galcanezumab vs. other therapies are required to better
explore its benefit-risk profile and comparative efficacy.
European Review for Medical and Pharmacological Sciences
Systematic literature review and Bayesian network meta-analysis of episodic cluster headache drugs
G Pompilio et al.
Comments (0)